Bristol-Myers Squibb Announces Departure of Chief Commercial Officer

Bristol-Myers Squibb Company BMY today announced that Murdo Gordon, executive vice president and chief commercial officer, is leaving the company, effective August 3, 2018, to pursue another opportunity.

"On behalf of the company, I want to thank Murdo for his leadership and the important contributions he's made in his many years with Bristol-Myers Squibb," said Giovanni Caforio, chairman and chief executive officer, Bristol-Myers Squibb. "Murdo helped build a highly performing commercial organization and developed a strong bench of talent, contributing to our competitive position in the market and our success in delivering innovative medicines to patients."

The announcement of a new chief commercial officer will be the subject of a separate communication at a later date.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180723005060/en/